Dr. Nagashree Seetharamu, MD

Dr. Seetharamu practices at Long Island Jewish Medical Center in New Hyde Park, New York.

Dr. Seetharamu's NPI, 1124198833, was assigned on November 9, 2006. Dr. Seetharamu holds New York license 241139.

Dr. Seetharamu's primary practice is Long Island Jewish Medical Center, at 27005 76th Ave, New Hyde Park, NY 11040 in Nassau County. The practice phone is (516) 876-6000.

Dr. Seetharamu's primary practice is Long Island Jewish Medical Center in New Hyde Park, New York. Dr. Seetharamu is also affiliated with Long Island Jewish Medical Center. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Seetharamu to 2 more hospitals, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Seetharamu practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Seetharamu's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Seetharamu is board certified in hospice and palliative medicine by the American Board of Anesthesiology. Dr. Seetharamu is licensed in New York.

CMS data shows 1,289 Medicare services from Dr. Seetharamu across 6 procedure codes in 2024, for 257 Medicare patients. Medicare paid $99,768 for them.

CMS counts 257 Medicare patients who saw Dr. Seetharamu in 2024. The largest group is 65 to 74, with 108 patients. 75% of them have cancer, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Seetharamu's median patient age at 73, with 54% women.

In 2024, Dr. Seetharamu wrote 637 Medicare Part D claims for 151 patients. 45% of them were for generic drugs. CMS names the drug for 464 of them, across 15 drugs with 11 or more claims each, at $3,721,361 in total drug cost. In 2023, CMS named 429 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Seetharamu for performance year 2024, reported through an alternative payment model (APM). Dr. Seetharamu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Seetharamu as offering telehealth.

Dmand AI links Dr. Seetharamu to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Neoplasm Metastasis and Neoplastic Processes. Open Payments lists research payments to Dr. Seetharamu that name 4 trials.

CMS Open Payments shows 78 general payments to Dr. Seetharamu from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. AstraZeneca Pharmaceuticals LP paid the most, $17,407. It also lists 8 research payments totaling $5,551 from 2023 to 2025, naming 4 clinical trials.